- Report
- August 2024
- 200 Pages
Global
From €2186EUR$2,290USD£1,831GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- September 2024
- 135 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- July 2024
- 100 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- October 2024
- 200 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- December 2024
- 144 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- August 2021
- 50 Pages
United States
From €2291EUR$2,400USD£1,919GBP
- Report
- April 2021
China
From €2481EUR$2,600USD£2,079GBP
- Report
- November 2018
- 30 Pages
China
From €2100EUR$2,200USD£1,759GBP
- Report
- August 2024
- 80 Pages
Japan
From €3340EUR$3,500USD£2,799GBP
- Report
- February 2024
- 181 Pages
Europe
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 176 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 160 Pages
Middle East, Africa
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 90 Pages
Europe
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 70 Pages
Germany
From €4533EUR$4,750USD£3,798GBP

Insulin Aspart is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. Insulin Aspart is a recombinant human insulin analog that is produced by recombinant DNA technology. It is a short-acting insulin that is used to control post-meal blood sugar levels. It is usually taken before meals and can be used in combination with other diabetes medications.
Insulin Aspart is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to control blood sugar levels, regulate hormones, and reduce the risk of complications associated with metabolic disorders.
Companies in the Insulin Aspart market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more